LOGIN  |  REGISTER
Recursion

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 405.27
8.00 2.01
1.30M
257.53M
US$ 104.370B
US$ 715.13
13.28 1.89
710,417
108.07M
US$ 77.280B
US$ 627.98
4.16 0.67
138,155
59.80M
US$ 37.550B
US$ 242.26
-3.18 -1.30
665,521
128.98M
US$ 31.250B
US$ 113.51
0.43 0.38
243,920
239.74M
US$ 27.210B
US$ 177.70
1.20 0.68
210,322
97.52M
US$ 17.330B
US$ 363.65
4.07 1.13
203,977
44.64M
US$ 16.230B
US$ 39.59
0.20 0.51
4.91M
384.82M
US$ 15.240B
US$ 136.99
1.57 1.16
1.02M
101.25M
US$ 13.870B
US$ 18.67
0.80 4.48
1.26M
737.45M
US$ 13.770B
US$ 69.84
1.00 1.45
1.41M
192.65M
US$ 13.450B
US$ 20.76
0.45 2.22
1.51M
635.24M
US$ 13.190B
US$ 66.27
0.61 0.93
859,135
190.58M
US$ 12.630B
US$ 70.59
0.15 0.21
796,343
178.90M
US$ 12.630B
US$ 72.74
-0.43 -0.59
499,111
158.89M
US$ 11.560B
US$ 120.66
1.69 1.42
348,728
95.52M
US$ 11.530B
US$ 25.25
0.33 1.32
6.10M
444.30M
US$ 11.220B
US$ 88.89
2.36 2.73
460,985
124.64M
US$ 11.080B
US$ 33.48
0.19 0.57
1.86M
285.58M
US$ 9.560B
US$ 84.00
0.55 0.66
213,786
106.02M
US$ 8.910B
US$ 11.97
0.40 3.46
7.78M
727.95M
US$ 8.710B
US$ 139.70
3.32 2.43
155,761
59.76M
US$ 8.350B
US$ 44.96
0.00 0.00
0
182.20M
US$ 8.190B
US$ 43.93
-0.13 -0.30
535,635
184.80M
US$ 8.120B
US$ 124.25
1.28 1.04
359,078
60.45M
US$ 7.510B
US$ 310.57
2.12 0.69
157,911
21.81M
US$ 6.770B
US$ 33.93
-0.15 -0.44
1.45M
183.45M
US$ 6.220B
US$ 47.14
0.18 0.38
1.03M
127.23M
US$ 6.000B
US$ 48.95
0.08 0.16
999,696
118.01M
US$ 5.780B
US$ 90.33
0.19 0.21
246,711
63.53M
US$ 5.740B
US$ 36.08
0.45 1.26
1.44M
157.90M
US$ 5.700B
US$ 83.85
-0.37 -0.44
309,906
65.62M
US$ 5.500B
US$ 50.90
-0.50 -0.97
640,751
104.78M
US$ 5.330B
US$ 27.77
1.28 4.83
1.17M
188.99M
US$ 5.250B
US$ 32.26
0.06 0.19
763,024
155.66M
US$ 5.020B
US$ 53.96
0.36 0.67
257,393
92.74M
US$ 5.000B
US$ 29.50
-0.21 -0.71
1.12M
161.80M
US$ 4.770B
US$ 160.83
-4.00 -2.43
187,268
28.76M
US$ 4.630B
US$ 86.95
-3.78 -4.17
911,650
48.46M
US$ 4.210B
US$ 17.72
0.32 1.84
2.06M
236.39M
US$ 4.190B
US$ 76.79
1.58 2.10
344,310
54.07M
US$ 4.150B
US$ 33.21
0.00 0.00
1.24M
124.39M
US$ 4.130B
US$ 43.96
-0.82 -1.83
758,304
93.62M
US$ 4.120B
US$ 27.44
0.20 0.73
951,170
149.57M
US$ 4.100B
US$ 43.87
-0.35 -0.79
484,370
92.34M
US$ 4.050B
US$ 25.76
-0.10 -0.39
563,733
146.78M
US$ 3.780B
US$ 12.52
0.61 5.12
96,467
301.94M
US$ 3.780B
US$ 31.64
-0.18 -0.57
1.16M
119.31M
US$ 3.770B
US$ 45.28
3.26 7.76
2.10M
81.83M
US$ 3.710B
US$ 36.15
-0.11 -0.30
802,827
101.12M
US$ 3.660B
US$ 40.48
-0.24 -0.59
1.13M
85.35M
US$ 3.450B
US$ 56.04
-0.08 -0.14
982,639
61.46M
US$ 3.440B
US$ 56.75
-0.08 -0.14
244,353
58.63M
US$ 3.330B
US$ 52.14
-0.03 -0.06
127,430
63.06M
US$ 3.290B
US$ 40.99
0.10 0.24
645,958
77.50M
US$ 3.180B
US$ 20.78
-0.67 -3.12
510,768
143.92M
US$ 2.990B
US$ 9.84
0.04 0.41
1.96M
298.81M
US$ 2.940B
US$ 42.45
0.60 1.43
433,820
68.46M
US$ 2.910B
US$ 38.14
-0.49 -1.27
273,718
76.24M
US$ 2.910B
US$ 17.17
0.44 2.63
1.06M
166.39M
US$ 2.860B
US$ 18.96
0.00 0.00
0
150.65M
US$ 2.860B
US$ 56.99
0.00 0.00
0
50.22M
US$ 2.860B
US$ 26.54
-0.18 -0.67
235,530
107.46M
US$ 2.850B
US$ 29.98
-0.80 -2.60
875,048
94.69M
US$ 2.840B
US$ 57.04
0.54 0.96
212,876
49.36M
US$ 2.820B
US$ 37.37
1.78 5.00
545,906
74.39M
US$ 2.780B
US$ 42.31
-0.29 -0.68
384,550
63.32M
US$ 2.680B
US$ 40.79
0.13 0.32
166,698
64.77M
US$ 2.640B
US$ 21.60
0.33 1.55
563,481
119.27M
US$ 2.580B
US$ 19.75
0.30 1.54
1.32M
124.43M
US$ 2.460B
US$ 23.91
-0.08 -0.33
303,589
101.77M
US$ 2.430B
US$ 40.60
-0.89 -2.15
718,557
59.60M
US$ 2.420B
US$ 28.70
-0.31 -1.07
461,395
82.81M
US$ 2.380B
US$ 25.63
0.13 0.51
350,358
92.39M
US$ 2.370B
US$ 17.53
0.37 2.16
299,447
131.84M
US$ 2.310B
US$ 7.46
0.08 1.08
16.46M
304.78M
US$ 2.270B
US$ 25.38
-0.23 -0.90
978,905
86.43M
US$ 2.190B
US$ 113.80
-0.84 -0.73
94,125
18.90M
US$ 2.150B
US$ 54.41
1.50 2.84
393,679
38.23M
US$ 2.080B
US$ 60.00
0.00 0.00
0
34.29M
US$ 2.060B
US$ 47.50
-0.21 -0.44
209,271
43.42M
US$ 2.060B
US$ 35.35
-0.07 -0.20
767,894
57.03M
US$ 2.020B
US$ 3.34
-0.15 -4.30
39.50M
604.50M
US$ 2.020B
US$ 17.49
2.86 19.55
1.17M
114.18M
US$ 2.000B
US$ 41.73
0.22 0.53
185,453
48.00M
US$ 2.000B
US$ 13.12
-0.39 -2.89
667,270
152.52M
US$ 2.000B
US$ 34.95
0.67 1.95
328,435
57.03M
US$ 1.990B
US$ 28.37
-0.97 -3.31
1.13M
69.80M
US$ 1.980B
US$ 2.67
0.05 1.91
10.54M
730.16M
US$ 1.950B
US$ 62.82
-1.30 -2.03
13,625
30.88M
US$ 1.940B
US$ 7.02
0.17 2.48
3.11M
275.78M
US$ 1.940B
US$ 44.95
-0.23 -0.51
383,191
43.12M
US$ 1.940B
US$ 63.81
-0.69 -1.07
131,845
29.76M
US$ 1.900B
US$ 28.13
-0.54 -1.88
302,263
67.63M
US$ 1.900B
US$ 11.12
0.27 2.49
673,015
161.56M
US$ 1.800B
US$ 27.09
0.33 1.23
165,019
65.90M
US$ 1.790B
US$ 14.97
-0.02 -0.13
2.12M
117.04M
US$ 1.750B
US$ 19.76
0.36 1.86
466,112
88.07M
US$ 1.740B
US$ 24.57
0.44 1.82
315,306
69.98M
US$ 1.720B
US$ 12.83
0.11 0.86
1.15M
131.46M
US$ 1.690B
US$ 18.77
-0.49 -2.54
708,342
89.70M
US$ 1.680B
US$ 24.77
-0.37 -1.47
846,533
66.34M
US$ 1.640B
US$ 28.58
0.68 2.44
822,806
57.26M
US$ 1.640B
US$ 7.78
0.21 2.77
2.09M
207.13M
US$ 1.610B
US$ 19.67
0.64 3.36
925,421
79.21M
US$ 1.560B
US$ 17.15
-0.03 -0.17
1.40M
87.03M
US$ 1.490B
US$ 15.96
0.46 2.97
529,993
91.51M
US$ 1.460B
US$ 77.57
1.05 1.37
196,082
18.64M
US$ 1.450B
US$ 19.98
0.15 0.76
225,952
70.84M
US$ 1.420B
US$ 28.14
-0.18 -0.64
222,286
50.03M
US$ 1.410B
US$ 23.59
-0.27 -1.13
291,712
58.71M
US$ 1.380B
US$ 8.64
-0.06 -0.69
2.08M
160.18M
US$ 1.380B
US$ 8.56
0.06 0.71
683,419
157.22M
US$ 1.350B
US$ 8.95
-0.08 -0.89
914,270
143.18M
US$ 1.280B
US$ 12.69
-0.10 -0.78
683,473
100.85M
US$ 1.280B
US$ 18.00
-0.48 -2.60
470,115
68.71M
US$ 1.240B
US$ 12.10
-0.08 -0.66
1.67M
101.85M
US$ 1.230B
US$ 11.43
-0.13 -1.12
777,283
106.34M
US$ 1.220B
US$ 13.31
0.23 1.76
4.90M
85.36M
US$ 1.140B
US$ 23.43
0.96 4.27
141,346
48.86M
US$ 1.140B
US$ 17.79
-0.05 -0.28
516,695
62.60M
US$ 1.110B
US$ 11.20
0.02 0.18
2.06M
97.19M
US$ 1.090B
US$ 4.58
-0.24 -4.98
2.90M
236.85M
US$ 1.080B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 12.20
1.06 9.52
92,361
85.82M
US$ 1.050B
US$ 18.93
-0.64 -3.27
17,592
54.23M
US$ 1.030B
US$ 7.34
0.00 0.00
837,931
137.72M
US$ 1.010B
US$ 14.28
0.14 0.99
541,973
68.88M
US$ 983.610M
US$ 11.44
0.34 3.06
512,104
84.64M
US$ 968.280M
US$ 12.34
-0.15 -1.20
682,674
76.96M
US$ 949.690M
US$ 11.18
2.55 29.55
13.07M
84.80M
US$ 948.060M
US$ 7.99
0.05 0.63
1.28M
117.58M
US$ 939.460M
US$ 6.32
-0.07 -1.10
607,228
147.58M
US$ 932.710M
US$ 9.48
0.03 0.32
669,942
97.47M
US$ 924.020M
US$ 2.67
-0.01 -0.37
2.26M
335.57M
US$ 895.970M
US$ 26.03
-0.06 -0.23
128,195
33.70M
US$ 877.210M
US$ 2.92
-0.09 -2.99
2.94M
295.37M
US$ 862.480M
US$ 7.07
0.22 3.21
441,529
121.55M
US$ 859.360M
US$ 7.76
-0.08 -1.02
1.47M
110.46M
US$ 857.170M
US$ 17.43
0.45 2.65
1.15M
48.74M
US$ 849.540M
US$ 15.33
0.11 0.72
460,591
53.81M
US$ 824.910M
US$ 13.34
0.13 0.98
570,044
60.85M
US$ 811.740M
US$ 12.27
-0.03 -0.24
646,473
63.96M
US$ 784.790M
US$ 5.13
-0.24 -4.47
1.54M
141.84M
US$ 727.640M
US$ 4.34
0.18 4.33
2.86M
167.38M
US$ 726.430M
US$ 14.25
0.25 1.79
137,889
50.60M
US$ 721.050M
US$ 10.43
1.33 14.62
16,269
67.84M
US$ 707.570M
US$ 16.83
-0.16 -0.94
37,738
41.94M
US$ 705.640M
US$ 2.48
-0.06 -2.36
2.31M
282.73M
US$ 701.170M
US$ 8.94
-0.07 -0.78
1.05M
77.76M
US$ 695.170M
US$ 17.12
0.09 0.53
876,205
40.51M
US$ 693.530M
US$ 14.54
-0.14 -0.95
796,529
47.55M
US$ 691.380M
US$ 11.87
0.27 2.33
603,398
58.23M
US$ 691.190M
US$ 23.18
-0.62 -2.61
153,883
29.60M
US$ 686.130M
US$ 10.97
0.00 0.00
520,394
62.42M
US$ 684.750M
US$ 14.72
-0.18 -1.21
226,810
46.03M
US$ 677.560M
US$ 2.96
0.09 3.14
348,990
224.34M
US$ 664.050M
US$ 18.03
-0.04 -0.22
26,934
36.58M
US$ 659.540M
US$ 17.46
-0.13 -0.74
62,024
37.42M
US$ 653.350M
US$ 14.13
1.06 8.11
1.39M
45.47M
US$ 642.490M
US$ 4.84
0.00 0.00
0
130.82M
US$ 633.170M
US$ 11.61
-0.07 -0.60
351,504
52.97M
US$ 614.980M
US$ 3.19
-0.02 -0.62
390,520
189.49M
US$ 604.470M
US$ 12.06
-0.28 -2.27
379,160
49.77M
US$ 600.230M
US$ 4.63
-0.01 -0.22
12.08M
128.67M
US$ 595.740M
US$ 8.33
0.12 1.46
435,602
70.57M
US$ 587.850M
US$ 10.11
-0.20 -1.94
989,622
57.95M
US$ 585.870M
US$ 2.18
-0.11 -4.80
7.01M
266.12M
US$ 580.140M
US$ 5.28
0.05 0.96
1.13M
106.59M
US$ 562.800M
US$ 3.25
0.02 0.62
1.78M
171.62M
US$ 557.760M
US$ 3.61
0.27 8.05
7,487
153.89M
US$ 555.390M
US$ 7.76
-0.49 -5.94
4.03M
71.12M
US$ 551.890M
US$ 21.30
0.65 3.15
176,161
25.64M
US$ 546.130M
US$ 3.37
0.02 0.60
1.07M
155.15M
US$ 522.860M
US$ 7.61
0.16 2.15
938,110
68.38M
US$ 520.370M
US$ 7.08
-0.08 -1.12
987,894
73.33M
US$ 519.180M
US$ 8.42
-0.15 -1.75
515,170
60.68M
US$ 510.930M
US$ 3.42
-0.07 -2.01
1.23M
149.08M
US$ 509.850M
US$ 5.90
0.16 2.79
1.19M
84.66M
US$ 499.490M
US$ 2.39
-0.08 -3.24
20.73M
208.65M
US$ 498.670M
US$ 7.25
0.15 2.11
323,921
68.25M
US$ 494.810M
US$ 19.35
0.33 1.74
38,674
25.41M
US$ 491.680M
US$ 9.25
0.60 6.94
450,740
52.62M
US$ 486.740M
US$ 10.80
-0.70 -6.09
117,088
45.06M
US$ 486.650M
US$ 9.79
0.20 2.09
145,125
49.17M
US$ 481.370M
US$ 19.92
-0.36 -1.78
1,497
23.94M
US$ 476.880M
US$ 6.09
-0.06 -0.98
169,549
78.15M
US$ 475.930M
US$ 7.35
-0.41 -5.28
1.49M
63.34M
US$ 465.550M
US$ 6.30
0.20 3.28
685,129
73.81M
US$ 465.000M
US$ 12.40
-0.06 -0.48
296,691
37.13M
US$ 460.410M
US$ 8.58
0.09 1.06
406,657
53.38M
US$ 458.000M
US$ 10.71
0.07 0.66
329,242
42.20M
US$ 451.960M
US$ 16.51
1.03 6.65
286,278
27.09M
US$ 447.260M
US$ 2.24
0.05 2.28
9.78M
197.04M
US$ 441.370M
US$ 7.14
0.21 3.03
1.09M
61.44M
US$ 438.680M
US$ 8.83
0.47 5.62
767,350
49.42M
US$ 436.380M
US$ 9.46
-0.62 -6.15
1.76M
45.20M
US$ 427.590M
US$ 13.97
-0.58 -3.99
543,671
30.43M
US$ 425.110M
US$ 5.94
-0.24 -3.88
378,325
71.40M
US$ 424.120M
US$ 3.49
-0.01 -0.29
245,375
121.01M
US$ 422.320M
US$ 5.95
0.20 3.48
2.04M
70.65M
US$ 420.370M
US$ 1.95
0.08 4.28
9.40M
209.67M
US$ 408.860M
US$ 8.18
-0.02 -0.24
81,579
49.95M
US$ 408.590M
US$ 43.29
-0.38 -0.87
33,270
9.37M
US$ 405.630M
US$ 5.30
-0.19 -3.46
432,710
76.38M
US$ 404.810M
US$ 1.85
0.02 1.09
5.82M
218.18M
US$ 403.630M
US$ 4.93
-0.35 -6.63
703,724
81.38M
US$ 401.200M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 1.83
-0.02 -1.08
2.24M
204.94M
US$ 375.040M
US$ 2.81
-0.09 -3.10
1.34M
131.16M
US$ 368.560M
US$ 7.38
-0.24 -3.15
1.87M
49.55M
US$ 365.680M
US$ 1.63
-0.02 -1.21
2.20M
223.27M
US$ 363.930M
US$ 6.99
0.14 2.04
57,821
52.03M
US$ 363.690M
US$ 8.11
-0.17 -2.05
319,386
44.79M
US$ 363.250M
US$ 6.21
-0.04 -0.64
77,244
56.62M
US$ 351.610M
US$ 3.23
0.13 4.19
893,314
107.42M
US$ 346.970M
US$ 0.26
0.0019 0.73
1.31M
1.30B
US$ 340.600M
US$ 2.93
0.01 0.34
3.90M
114.86M
US$ 336.540M
US$ 22.50
-0.14 -0.62
184,159
14.85M
US$ 334.120M
US$ 5.44
-0.17 -3.03
929,910
61.17M
US$ 332.760M
US$ 22.03
0.46 2.13
199,616
15.00M
US$ 330.450M
US$ 4.04
0.05 1.25
40,751
81.20M
US$ 328.050M
US$ 3.59
-0.06 -1.64
1.36M
91.18M
US$ 327.340M
US$ 12.50
-0.07 -0.56
98,372
25.84M
US$ 323.000M
US$ 3.07
-0.02 -0.65
13.65M
104.39M
US$ 320.480M
US$ 3.18
0.03 0.95
518,419
100.33M
US$ 319.050M
US$ 26.62
-0.51 -1.88
22,204
11.78M
US$ 313.580M
US$ 5.73
-0.02 -0.35
248,650
54.63M
US$ 313.030M
US$ 4.06
0.01 0.25
754,041
76.87M
US$ 312.090M
US$ 17.15
0.06 0.35
112,874
17.61M
US$ 302.010M
US$ 0.83
0.12 16.13
10.31M
361.49M
US$ 300.040M
US$ 1.58
0.00 0.00
1.18M
185.72M
US$ 293.440M
US$ 4.55
-0.44 -8.82
1.31M
64.26M
US$ 292.380M
US$ 1.98
-0.05 -2.46
226,516
145.46M
US$ 288.010M
US$ 4.79
-0.09 -1.84
155,198
59.55M
US$ 285.240M
US$ 2.68
0.05 1.90
191,965
105.91M
US$ 283.840M
US$ 3.38
0.03 0.90
2.09M
83.94M
US$ 283.720M
US$ 8.63
-0.12 -1.37
2.64M
32.48M
US$ 280.300M
US$ 4.07
0.02 0.49
251,223
68.55M
US$ 279.000M
US$ 4.93
-0.21 -4.09
110,488
55.59M
US$ 274.060M
US$ 3.24
0.05 1.57
386,837
84.46M
US$ 273.650M
US$ 4.68
-0.10 -2.09
1.12M
58.31M
US$ 272.890M
US$ 5.88
-0.43 -6.81
1.15M
46.23M
US$ 271.830M
US$ 14.14
0.64 4.74
44,450
19.05M
US$ 269.370M
US$ 7.35
-0.07 -0.94
347,498
36.53M
US$ 268.500M
US$ 2.68
-0.02 -0.74
109,557
98.94M
US$ 265.160M
US$ 11.12
-0.29 -2.54
134,375
23.22M
US$ 258.210M
US$ 4.44
0.05 1.14
248,858
57.94M
US$ 257.250M
US$ 23.40
0.18 0.78
70,165
10.94M
US$ 256.000M
US$ 3.96
-0.05 -1.25
546,545
63.81M
US$ 252.690M
US$ 4.68
0.33 7.59
7.80M
53.94M
US$ 252.440M
US$ 4.19
-0.17 -3.90
441,698
59.74M
US$ 250.310M
US$ 5.67
-0.72 -11.27
162,850
43.47M
US$ 246.470M
US$ 1.60
0.02 1.27
3.65M
152.10M
US$ 243.360M
US$ 16.23
-0.08 -0.49
46,987
14.65M
US$ 237.770M
US$ 38.69
0.04 0.10
27,966
6.08M
US$ 235.240M
US$ 5.38
-1.04 -16.22
203,120
42.76M
US$ 229.840M
US$ 3.18
0.18 6.00
1.53M
71.27M
US$ 226.640M
US$ 6.51
-0.39 -5.65
285,862
34.08M
US$ 221.860M
US$ 0.75
-0.02 -2.18
5.05M
292.87M
US$ 218.480M
US$ 1.69
0.18 11.92
659,169
127.97M
US$ 216.270M
US$ 1.72
-0.04 -2.27
861,683
125.56M
US$ 215.960M
US$ 3.08
-0.02 -0.65
60,638
70.10M
US$ 215.910M
US$ 0.74
-0.03 -4.43
7.73M
291.32M
US$ 215.580M
US$ 5.94
-0.20 -3.26
1.58M
35.85M
US$ 212.950M
US$ 14.47
-0.13 -0.89
42,182
14.48M
US$ 209.530M
US$ 4.07
-0.19 -4.46
1.42M
51.13M
US$ 208.100M
US$ 2.89
0.12 4.33
3.82M
71.43M
US$ 206.430M
US$ 6.21
-0.07 -1.11
102,753
33.08M
US$ 205.430M
C$ 2.90
-0.10 -3.33
51,158
70.31M
C$ 203.900M
US$ 3.23
0.05 1.57
598,852
62.76M
US$ 202.710M
US$ 1.20
0.01 0.84
1.14M
167.80M
US$ 201.360M
US$ 2.96
-0.24 -7.50
167,857
67.19M
US$ 198.880M
US$ 6.36
-0.33 -4.93
45,005
31.14M
US$ 198.050M
US$ 0.86
0.02 2.14
2.94M
226.60M
US$ 194.420M
US$ 3.01
0.02 0.67
525,550
64.24M
US$ 193.360M
US$ 1.56
-0.04 -2.50
1.09M
123.53M
US$ 192.710M
US$ 1.99
0.03 1.53
900,767
96.69M
US$ 192.410M
US$ 9.54
-0.07 -0.73
270,584
19.99M
US$ 190.700M
US$ 17.67
1.18 7.16
56,385
10.79M
US$ 190.660M
US$ 1.66
-0.02 -1.19
7.96M
113.89M
US$ 189.060M
US$ 1.93
0.07 3.76
1.14M
97.93M
US$ 189.000M
US$ 3.77
-0.03 -0.84
4,933
49.91M
US$ 188.060M
US$ 0.46
-0.004 -0.87
4.12M
411.34M
US$ 187.570M
US$ 5.08
0.00 0.00
0
36.86M
US$ 187.250M
US$ 5.25
-0.14 -2.60
1.06M
34.32M
US$ 180.150M
US$ 0.62
0.0033 0.54
788,437
292.16M
US$ 179.970M
US$ 1.12
-0.52 -31.71
3.46M
158.72M
US$ 177.770M
US$ 4.69
-0.23 -4.67
41,025
37.82M
US$ 177.380M
US$ 2.50
0.13 5.49
5.49M
70.57M
US$ 176.420M
US$ 3.96
-0.23 -5.49
1.12M
44.51M
US$ 176.260M
US$ 2.10
0.05 2.44
29,374
82.78M
US$ 173.840M
US$ 3.42
0.03 0.88
605,611
50.04M
US$ 171.140M
US$ 3.54
-0.21 -5.60
1.35M
48.13M
US$ 170.380M
US$ 6.21
0.22 3.67
101,770
27.43M
US$ 170.340M
US$ 3.92
-0.08 -2.00
162,951
43.17M
US$ 169.230M
US$ 2.35
0.11 4.91
1.49M
70.71M
US$ 166.170M
US$ 0.90
-0.03 -3.05
6.68M
184.46M
US$ 166.010M
US$ 1.43
-0.09 -5.92
2.98M
115.21M
US$ 164.750M
US$ 4.10
-0.06 -1.44
939,110
39.95M
US$ 163.790M
US$ 12.44
0.04 0.32
24,509
13.14M
US$ 163.400M
US$ 1.79
-0.01 -0.56
1.20M
90.55M
US$ 162.080M
US$ 0.95
0.03 3.33
3.03M
170.74M
US$ 161.520M
US$ 13.16
0.16 1.23
217,772
12.18M
US$ 160.290M
US$ 1.57
-0.07 -4.15
11,639
100.09M
US$ 157.340M
C$ 4.40
0.07 1.62
7,300
35.62M
C$ 156.730M
US$ 2.38
0.10 4.39
1.11M
65.29M
US$ 155.390M
US$ 2.99
-0.15 -4.78
325,538
51.59M
US$ 154.250M
US$ 1.87
-0.01 -0.53
793,091
82.46M
US$ 154.200M
US$ 7.58
2.38 45.77
230,742
20.16M
US$ 152.810M
US$ 4.97
0.02 0.40
340,147
30.67M
US$ 152.430M
US$ 0.59
-0.02 -2.79
3.34M
255.88M
US$ 150.460M
US$ 3.01
0.04 1.35
281,791
49.09M
US$ 147.760M
US$ 3.94
-0.11 -2.72
2.45M
37.42M
US$ 147.430M
US$ 2.50
0.26 11.61
229,964
58.88M
US$ 147.200M
US$ 4.03
-0.20 -4.73
456,663
36.24M
US$ 146.050M
US$ 21.72
1.11 5.39
72,081
6.53M
US$ 141.830M
US$ 2.98
-0.12 -3.87
41,309
47.40M
US$ 141.250M
C$ 1.78
0.07 4.09
21,219
78.16M
C$ 139.120M
US$ 4.64
-0.54 -10.42
325,863
29.75M
US$ 138.040M
US$ 2.81
0.06 2.18
263,400
49.09M
US$ 137.940M
US$ 4.50
-1.88 -29.47
511,375
30.48M
US$ 137.160M
US$ 0.60
-0.02 -3.00
1.08M
227.48M
US$ 136.720M
US$ 1.52
-0.01 -0.65
645,459
89.54M
US$ 136.100M
US$ 6.37
0.09 1.43
335,473
21.19M
US$ 134.980M
US$ 38.85
-0.99 -2.48
530,958
3.46M
US$ 134.420M
US$ 3.78
-0.04 -1.05
193,808
34.39M
US$ 129.990M
US$ 1.75
-0.02 -0.85
339,525
73.63M
US$ 128.480M
US$ 3.89
0.26 7.16
82,172
32.60M
US$ 126.810M
US$ 24.00
-1.82 -7.05
18,088
5.28M
US$ 126.720M
US$ 1.59
-0.08 -4.79
16.37M
79.22M
US$ 125.960M
US$ 1.00
0.04 3.77
1.24M
125.80M
US$ 125.800M
US$ 2.26
-0.05 -2.16
120,997
54.92M
US$ 124.120M
US$ 2.19
-0.03 -1.35
421,694
56.59M
US$ 123.930M
US$ 0.55
-0.01 -1.79
3.95M
220.42M
US$ 120.790M
US$ 7.75
0.00 0.00
0
15.53M
US$ 120.360M
C$ 1.79
0.02 1.13
14,214
64.94M
C$ 116.240M
US$ 2.41
0.06 2.55
6.14M
48.11M
US$ 115.950M
US$ 2.21
-0.14 -6.04
9,217
52.36M
US$ 115.610M
US$ 2.36
-0.02 -0.84
1.95M
48.88M
US$ 115.360M
US$ 1.29
0.09 7.50
1.11M
89.34M
US$ 115.250M
US$ 2.89
-0.02 -0.69
183,926
38.32M
US$ 110.740M
US$ 8.11
0.61 8.13
267,624
13.59M
US$ 110.210M
US$ 4.00
0.11 2.83
188,576
26.97M
US$ 107.880M
US$ 1.77
-0.03 -1.67
1.60M
60.08M
US$ 106.340M
US$ 2.12
-0.05 -2.30
86,129
49.05M
US$ 103.990M
US$ 1.25
-0.06 -4.58
2.65M
82.55M
US$ 103.190M
C$ 0.89
0.04 4.71
388,020
113.60M
C$ 101.100M
US$ 4.55
0.15 3.41
273,087
22.17M
US$ 100.870M
US$ 1.53
-0.06 -3.77
342,789
65.50M
US$ 100.220M
US$ 1.67
-0.02 -1.18
963,119
59.47M
US$ 99.310M
US$ 1.85
0.05 2.78
296,067
53.33M
US$ 98.660M
US$ 1.87
0.25 15.43
5.52M
52.74M
US$ 98.620M
US$ 4.74
0.00 0.00
138,080
20.80M
US$ 98.590M
US$ 0.58
-0.03 -5.61
16.50M
170.55M
US$ 98.410M
US$ 1.07
0.07 7.00
867,314
90.08M
US$ 96.390M
US$ 2.38
0.01 0.42
376,268
40.31M
US$ 95.940M
US$ 0.82
-0.06 -6.37
26.07M
116.36M
US$ 95.880M
US$ 9.09
0.18 2.02
178,922
10.46M
US$ 95.080M
US$ 14.83
-0.38 -2.50
15,611
6.36M
US$ 94.320M
US$ 1.86
0.00 0.00
695,143
49.81M
US$ 92.650M
US$ 1.90
0.11 6.15
447,021
48.10M
US$ 91.390M
US$ 4.90
-0.11 -2.20
12,152
18.29M
US$ 89.570M
US$ 5.31
0.07 1.34
19,003
16.71M
US$ 88.730M
C$ 3.23
-0.15 -4.44
18,610
27.40M
C$ 88.500M
US$ 4.58
0.06 1.33
122,192
19.32M
US$ 88.490M
US$ 1.02
-0.08 -7.27
607,540
85.03M
US$ 86.730M
US$ 1.09
0.00 0.00
4.30M
78.26M
US$ 85.300M
US$ 2.62
-0.07 -2.60
85,976
32.18M
US$ 84.310M
US$ 1.88
-0.17 -8.29
71,779
44.27M
US$ 83.230M
US$ 3.79
-0.18 -4.53
60,680
21.24M
US$ 80.500M
US$ 2.63
-0.07 -2.59
839,588
30.34M
US$ 79.790M
US$ 1.65
0.10 6.45
16.27M
48.26M
US$ 79.630M
US$ 2.30
0.03 1.32
103,561
34.54M
US$ 79.440M
US$ 0.97
0.05 5.42
247,889
81.50M
US$ 79.300M
US$ 22.10
21.00 1.00
2,692
3.55M
US$ 78.460M
US$ 1.51
0.01 0.67
255,122
51.75M
US$ 78.140M
US$ 1.76
-0.02 -1.12
140,913
44.00M
US$ 77.440M
US$ 0.62
-0.02 -2.99
1.38M
125.32M
US$ 77.200M
US$ 0.40
-0.21 -33.94
179.68M
186.89M
US$ 75.500M
US$ 7.66
-0.84 -9.88
426,497
9.72M
US$ 74.460M
US$ 2.56
0.03 1.19
227,574
28.91M
US$ 74.010M
US$ 0.89
0.03 3.92
752,760
82.40M
US$ 73.670M
US$ 2.00
-0.10 -4.76
477,342
36.83M
US$ 73.660M
US$ 0.98
-0.04 -3.92
17.29M
75.00M
US$ 73.500M
US$ 1.10
-0.09 -7.56
352,566
66.79M
US$ 73.470M
US$ 2.10
-0.15 -6.67
199,833
34.66M
US$ 72.790M
US$ 1.63
0.03 1.88
149,133
44.39M
US$ 72.360M
US$ 1.55
0.00 0.00
0
46.60M
US$ 72.230M
C$ 0.22
-0.01 -4.35
89,729
325.32M
C$ 71.570M
US$ 2.57
0.07 2.80
4.46M
27.84M
US$ 71.550M
US$ 1.98
0.03 1.28
49,911
36.18M
US$ 71.460M
US$ 0.68
-0.09 -12.00
1.39M
103.82M
US$ 70.810M
US$ 1.75
0.16 10.06
18,091
40.30M
US$ 70.530M
US$ 2.86
0.52 22.22
1.17M
24.65M
US$ 70.500M
US$ 12.20
0.80 7.02
144,833
5.76M
US$ 70.270M
US$ 1.57
-0.02 -1.26
448,908
44.56M
US$ 69.960M
US$ 0.91
0.08 9.03
4.31M
77.07M
US$ 69.830M
US$ 2.22
0.06 2.78
3,555
31.24M
US$ 69.350M
US$ 0.66
-0.02 -3.07
2.63M
103.80M
US$ 68.820M
US$ 2.20
0.20 10.00
1.19M
31.05M
US$ 68.310M
US$ 3.30
0.11 3.29
44,749
20.52M
US$ 67.610M
US$ 0.95
-0.05 -4.91
1.42M
71.01M
US$ 67.460M
US$ 0.88
0.0077 0.88
786,426
75.84M
US$ 66.740M
US$ 1.58
-0.12 -7.06
624,253
40.88M
US$ 64.590M
US$ 2.72
-0.11 -3.89
569,833
23.61M
US$ 64.220M
US$ 0.91
0.02 2.36
665,721
70.38M
US$ 63.980M
US$ 0.70
0.0098 1.41
2.75M
90.56M
US$ 63.750M
US$ 1.67
0.02 1.21
415,509
37.41M
US$ 62.470M
US$ 4.46
0.09 2.06
213,860
13.80M
US$ 61.550M
US$ 0.87
0.0027 0.31
186,061
68.67M
US$ 59.740M
US$ 2.56
0.00 0.00
0
23.12M
US$ 59.190M
US$ 1.69
0.86 104.75
339.72M
34.96M
US$ 59.080M
US$ 0.89
0.12 15.43
582,373
65.88M
US$ 58.630M
US$ 3.07
0.11 3.72
24,753
19.08M
US$ 58.580M
US$ 1.35
0.03 2.27
645,115
42.51M
US$ 57.390M
US$ 0.95
-0.0079 -0.82
114,613
60.34M
US$ 57.320M
US$ 2.56
-0.03 -1.16
126,148
22.30M
US$ 57.090M
US$ 0.47
0.03 6.10
975,478
119.62M
US$ 56.340M
US$ 3.29
0.11 3.46
156,844
17.06M
US$ 56.130M
US$ 0.89
-0.15 -14.42
2.80M
62.76M
US$ 55.860M
US$ 1.01
0.06 5.90
4,215
55.25M
US$ 55.640M
US$ 4.40
0.00 0.00
0
12.54M
US$ 55.180M
US$ 5.09
0.21 4.30
10,524
10.79M
US$ 54.920M
US$ 1.64
0.30 22.39
17.65M
33.44M
US$ 54.840M
C$ 0.40
0.00 0.00
171,023
134.53M
C$ 53.810M
US$ 1.80
0.05 2.63
118,422
29.59M
US$ 53.140M
C$ 0.08
-0.01 -11.76
127,960
701.73M
C$ 52.630M
US$ 1.10
-0.05 -4.35
124,710
47.74M
US$ 52.510M
US$ 1.24
-0.06 -4.62
1.45M
42.18M
US$ 52.300M
US$ 0.45
0.05 11.39
2.16M
115.57M
US$ 52.010M
US$ 2.28
-0.05 -2.15
564,845
22.48M
US$ 51.250M
C$ 0.72
0.02 2.86
34,252
70.89M
C$ 51.040M
US$ 19.54
0.87 4.66
98,725
2.61M
US$ 51.000M
US$ 0.92
-0.03 -3.36
709,308
54.52M
US$ 50.320M
US$ 5.32
-0.68 -11.33
24,857
9.39M
US$ 49.950M
US$ 1.97
-0.05 -2.48
438,126
25.33M
US$ 49.900M
US$ 1.78
0.01 0.56
849,566
27.52M
US$ 48.990M
US$ 1.11
-0.17 -13.28
1.30M
43.96M
US$ 48.800M
US$ 0.48
0.08 20.00
4.23M
100.77M
US$ 48.370M
US$ 1.74
0.02 1.16
653,695
27.60M
US$ 48.020M
US$ 1.44
0.04 2.50
481,639
33.31M
US$ 47.800M
C$ 0.97
0.00 0.00
0
49.02M
C$ 47.550M
US$ 6.44
0.06 0.94
60,884
7.30M
US$ 47.010M
US$ 1.79
-0.05 -2.72
1.10M
26.10M
US$ 46.720M
C$ 3.95
0.00 0.00
0
11.82M
C$ 46.690M
US$ 1.16
0.05 4.50
27,626
40.23M
US$ 46.670M
US$ 0.83
-0.0079 -0.94
270,529
55.37M
US$ 45.900M
US$ 0.70
-0.03 -4.37
569,669
63.81M
US$ 44.540M
US$ 3.98
-0.10 -2.45
28,051
11.11M
US$ 44.220M
US$ 4.71
0.30 6.80
1,492
8.91M
US$ 41.970M
C$ 0.24
0.00 0.00
0
174.66M
C$ 41.920M
US$ 1.57
0.01 0.64
268,193
26.53M
US$ 41.650M
US$ 1.03
0.06 5.77
2.60M
40.44M
US$ 41.650M
US$ 2.68
0.03 1.13
17,986
15.46M
US$ 41.430M
US$ 1.13
-0.03 -2.59
16,537
36.18M
US$ 40.880M
US$ 1.88
0.13 7.66
181,973
21.67M
US$ 40.830M
US$ 0.98
0.001 0.10
23,976
41.09M
US$ 40.310M
US$ 0.65
-0.01 -1.82
211,169
61.77M
US$ 40.030M
US$ 12.17
1.61 15.25
25,870
3.25M
US$ 39.550M
C$ 0.53
-0.09 -14.52
31,500
74.57M
C$ 39.520M
US$ 3.44
0.03 0.88
26,799
11.45M
US$ 39.390M
US$ 1.24
-0.05 -3.88
300,897
31.20M
US$ 38.690M
US$ 2.20
-0.03 -1.35
55,887
17.45M
US$ 38.390M
US$ 2.57
0.07 2.60
537,062
14.75M
US$ 37.830M
US$ 0.91
-0.04 -4.11
176,512
41.49M
US$ 37.800M
US$ 4.72
0.32 7.27
41,049
7.98M
US$ 37.670M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 2.78
0.02 0.72
17,934
13.48M
US$ 37.470M
US$ 1.34
0.91 212.35
14.63M
27.86M
US$ 37.330M
US$ 2.21
0.02 0.68
9,738
16.84M
US$ 37.130M
US$ 0.84
0.13 18.04
15.10M
43.64M
US$ 36.660M
US$ 13.86
-1.10 -7.35
11,231
2.61M
US$ 36.170M
US$ 2.02
0.12 6.32
1.80M
17.77M
US$ 35.900M
US$ 1.06
0.00 0.00
18,470
33.84M
US$ 35.870M
US$ 1.48
0.04 2.78
1.88M
23.66M
US$ 35.020M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 4.52
-0.20 -4.24
102,078
7.67M
US$ 34.670M
C$ 0.46
0.09 24.66
1,500
74.76M
C$ 34.020M
US$ 0.57
-0.006 -1.03
1.35M
59.12M
US$ 33.930M
US$ 3.02
-0.13 -3.97
122,061
10.78M
US$ 32.560M
US$ 1.23
0.24 24.34
1.84M
25.93M
US$ 31.920M
US$ 1.65
-0.03 -1.79
44,332
18.86M
US$ 31.120M
US$ 3.42
-0.38 -10.00
61,492
8.92M
US$ 30.510M
US$ 1.27
0.02 1.60
27,421
24.00M
US$ 30.480M
C$ 0.27
0.02 5.88
23,555
111.72M
C$ 30.160M
US$ 0.92
-0.002 -0.22
5,694
32.69M
US$ 30.010M
US$ 1.96
0.08 4.10
33,719
15.10M
US$ 29.550M
US$ 0.61
-0.08 -11.74
2.50M
48.35M
US$ 29.540M
US$ 0.37
-0.005 -1.32
311,043
77.45M
US$ 28.970M
US$ 1.25
-0.11 -8.09
1.67M
23.13M
US$ 28.910M
C$ 0.19
0.00 0.00
0
148.22M
C$ 28.160M
US$ 19.00
-0.34 -1.76
51,575
1.46M
US$ 27.740M
US$ 3.27
0.19 6.17
93,266
8.47M
US$ 27.700M
US$ 3.18
0.47 17.34
88,434
8.70M
US$ 27.670M
US$ 5.99
0.07 1.18
12,780
4.61M
US$ 27.610M
US$ 2.71
0.46 20.44
165,162
10.17M
US$ 27.560M
US$ 2.37
-0.19 -7.42
2,286
11.54M
US$ 27.350M
US$ 1.24
0.00 0.00
121,695
21.99M
US$ 27.270M
C$ 0.59
-0.01 -1.67
2,500
46.03M
C$ 27.160M
US$ 0.94
-0.03 -2.99
49,432
28.01M
US$ 26.360M
US$ 0.98
-0.05 -4.47
204,468
26.30M
US$ 25.880M
C$ 0.54
-0.03 -5.26
11,500
47.65M
C$ 25.730M
US$ 4.80
-0.07 -1.44
60,053
5.35M
US$ 25.680M
US$ 3.05
0.34 12.55
20,389
8.39M
US$ 25.590M
C$ 0.20
-0.02 -9.09
13,000
127.82M
C$ 25.560M
US$ 3.75
0.53 16.30
19,906
6.80M
US$ 25.470M
US$ 4.58
-0.24 -4.98
13,797
5.56M
US$ 25.460M
US$ 0.61
-0.02 -2.87
12.28M
41.55M
US$ 25.430M
US$ 1.40
0.14 11.11
965,080
18.06M
US$ 25.280M
US$ 0.95
-0.02 -2.06
115,462
26.47M
US$ 25.150M
US$ 0.45
0.03 6.72
2.22M
54.86M
US$ 24.740M
US$ 1.41
0.05 3.68
432,277
17.52M
US$ 24.700M
US$ 0.60
-0.05 -7.85
136,071
39.97M
US$ 23.940M
US$ 14.26
-1.91 -11.81
59,421
1.66M
US$ 23.670M
US$ 1.77
0.12 7.27
288,239
13.35M
US$ 23.630M
C$ 0.24
0.005 2.13
64,208
96.40M
C$ 23.140M
US$ 0.64
0.003 0.47
463,931
35.36M
US$ 22.740M
US$ 0.64
-0.02 -3.63
563,020
34.82M
US$ 22.280M
US$ 1.72
0.15 9.24
71,789
12.85M
US$ 22.040M
US$ 1.53
0.04 2.68
3.27M
14.35M
US$ 21.960M
US$ 2.36
-0.12 -4.84
51,873
9.15M
US$ 21.590M
US$ 0.60
-0.01 -1.64
171,675
35.43M
US$ 21.190M
US$ 5.79
-0.21 -3.50
24,597
3.65M
US$ 21.130M
US$ 2.40
0.20 9.09
52,513
8.74M
US$ 20.980M
US$ 2.21
-0.08 -3.49
1.30M
9.44M
US$ 20.860M
US$ 2.36
0.00 0.00
0
8.49M
US$ 20.040M
C$ 0.23
0.01 4.65
88,500
88.52M
C$ 19.920M
US$ 0.55
-0.01 -2.50
815,805
36.31M
US$ 19.860M
US$ 0.52
-0.04 -7.16
335,819
38.27M
US$ 19.860M
US$ 0.51
-0.06 -10.94
315,779
38.67M
US$ 19.840M
US$ 2.03
0.01 0.50
84,082
9.66M
US$ 19.610M
US$ 1.19
0.00 0.00
424,639
16.39M
US$ 19.500M
US$ 0.49
-0.03 -6.30
110,494
39.55M
US$ 19.420M
US$ 5.49
-0.12 -2.14
3,158
3.41M
US$ 18.720M
US$ 0.22
0.02 8.87
5.71M
84.11M
US$ 18.590M
US$ 0.95
-0.02 -1.85
3.09M
19.55M
US$ 18.570M
US$ 4.00
0.03 0.76
130,255
4.59M
US$ 18.360M
US$ 2.21
-0.02 -0.90
451,839
8.25M
US$ 18.230M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 0.40
-0.05 -11.14
675,880
44.54M
US$ 17.770M
US$ 0.24
-0.0088 -3.54
647,082
72.48M
US$ 17.400M
US$ 10.80
9.00 500.00
1,722
1.61M
US$ 17.390M
US$ 1.42
-0.08 -5.33
395,855
12.09M
US$ 17.170M
US$ 1.00
0.04 4.19
123,948
16.85M
US$ 16.850M
C$ 0.07
-0.02 -18.75
110,692
258.84M
C$ 16.820M
US$ 0.35
0.005 1.47
759,674
48.35M
US$ 16.730M
US$ 0.40
-0.02 -4.52
306,615
41.75M
US$ 16.660M
US$ 1.38
-0.04 -2.68
4,675
11.70M
US$ 16.170M
US$ 2.90
-0.15 -4.92
27,561
5.43M
US$ 15.750M
US$ 2.36
-0.14 -5.60
294,947
6.66M
US$ 15.720M
US$ 0.38
-0.02 -5.50
872,329
41.30M
US$ 15.610M
C$ 0.06
0.00 0.00
11,000
280.65M
C$ 15.440M
US$ 4.76
0.66 16.10
260,072
3.21M
US$ 15.280M
US$ 0.25
-0.03 -10.75
31.23M
59.52M
US$ 14.820M
US$ 2.12
-0.05 -2.08
794,392
6.99M
US$ 14.780M
C$ 0.16
-0.005 -3.12
122,500
90.29M
C$ 13.990M
US$ 0.22
-0.02 -7.65
351,048
64.48M
US$ 13.930M
US$ 0.82
-0.007 -0.85
47,117
16.89M
US$ 13.820M
C$ 0.11
0.00 0.00
49,500
129.86M
C$ 13.640M
C$ 0.03
0.00 0.00
60,000
541.70M
C$ 13.540M
US$ 0.24
0.008 3.48
3.08M
55.19M
US$ 13.140M
C$ 0.10
-0.005 -5.00
24,500
137.51M
C$ 13.060M
US$ 0.03
0.001 3.23
28,531
407.29M
US$ 13.030M
US$ 2.97
-0.05 -1.66
17,895
4.35M
US$ 12.920M
US$ 0.25
-0.0051 -2.04
246,269
51.37M
US$ 12.590M
US$ 1.60
-0.04 -2.44
13,145
7.68M
US$ 12.290M
US$ 0.19
-0.002 -1.05
1.41M
63.78M
US$ 11.990M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.38
-0.02 -4.77
6.90M
31.06M
US$ 11.830M
US$ 2.05
-0.23 -10.09
180,163
5.70M
US$ 11.680M
US$ 0.98
0.05 5.56
719,960
11.80M
US$ 11.530M
US$ 0.79
-0.04 -4.70
385,796
14.50M
US$ 11.470M
US$ 0.46
0.0061 1.36
108,534
25.15M
US$ 11.470M
US$ 0.18
-0.005 -2.78
1.21M
65.46M
US$ 11.460M
US$ 0.38
0.02 4.71
551,420
30.17M
US$ 11.460M
US$ 0.28
0.04 17.45
4.26M
41.27M
US$ 11.390M
US$ 1.99
0.03 1.28
976
5.70M
US$ 11.310M
C$ 0.08
0.00 0.00
20,000
140.64M
C$ 11.250M
US$ 8.26
0.16 1.98
93,444
1.30M
US$ 10.740M
US$ 0.89
-0.05 -5.22
28,004
12.01M
US$ 10.680M
US$ 1.51
-0.04 -2.58
15,841
6.92M
US$ 10.450M
US$ 0.45
-0.04 -7.96
17,467
23.13M
US$ 10.450M
US$ 9.49
-0.26 -2.67
15,646
1.10M
US$ 10.440M
US$ 3.29
0.02 0.61
34,782
3.00M
US$ 9.870M
US$ 3.70
0.28 8.19
142,632
2.58M
US$ 9.550M
US$ 2.03
0.06 3.05
18,254
4.58M
US$ 9.300M
US$ 0.23
0.02 10.95
641,126
39.74M
US$ 9.260M
US$ 0.08
-0.0013 -1.52
9.72M
106.44M
US$ 8.940M
US$ 1.45
0.07 5.07
32,978
6.15M
US$ 8.920M
US$ 1.46
-0.02 -1.35
85,540
6.10M
US$ 8.910M
US$ 1.68
-0.43 -20.38
25,517
5.17M
US$ 8.690M
US$ 0.05
-0.0095 -15.97
111,800
172.20M
US$ 8.610M
US$ 3.17
-0.02 -0.63
251,454
2.71M
US$ 8.590M
US$ 1.92
0.17 9.71
364,696
4.34M
US$ 8.330M
US$ 0.03
0.00 0.00
0
261.79M
US$ 8.120M
US$ 6.32
-0.18 -2.77
15,743
1.28M
US$ 8.090M
US$ 0.16
-0.0038 -2.26
1.05M
48.77M
US$ 8.000M
US$ 0.93
0.02 2.42
201,777
8.51M
US$ 7.930M
US$ 0.09
-0.001 -1.12
6,000
85.78M
US$ 7.550M
C$ 0.16
0.00 0.00
0
44.79M
C$ 7.170M
US$ 2.84
-0.11 -3.73
63,579
2.51M
US$ 7.130M
US$ 0.47
0.02 4.19
67,927
14.54M
US$ 6.830M
US$ 0.20
-0.01 -4.88
1.33M
33.65M
US$ 6.630M
US$ 1.03
-0.04 -3.74
70,202
6.41M
US$ 6.600M
US$ 0.06
-0.02 -26.37
19.54M
119.86M
US$ 6.590M
US$ 0.53
0.01 2.38
75,649
12.24M
US$ 6.490M
US$ 4.80
0.10 2.13
11,554
1.32M
US$ 6.340M
US$ 4.09
-0.20 -4.66
8,302
1.54M
US$ 6.300M
US$ 1.05
-0.04 -3.67
38,860
5.90M
US$ 6.200M
US$ 0.11
-0.001 -0.93
5.26M
57.49M
US$ 6.150M
US$ 2.75
1.01 57.59
47.44M
2.23M
US$ 6.130M
US$ 5.39
-0.57 -9.56
175,885
1.12M
US$ 6.040M
US$ 0.14
-0.0015 -1.06
234,382
41.12M
US$ 5.760M
US$ 0.82
0.008 0.99
89,632
6.90M
US$ 5.640M
US$ 1.73
-0.004 -0.23
6,569
3.25M
US$ 5.610M
US$ 0.20
0.004 2.00
1.91M
26.83M
US$ 5.470M
US$ 1.22
0.02 1.67
34,095
4.38M
US$ 5.340M
US$ 0.91
-0.01 -1.30
51,914
5.87M
US$ 5.330M
US$ 3.25
0.00 0.00
0
1.61M
US$ 5.230M
US$ 0.64
-0.02 -3.64
2.77M
8.21M
US$ 5.220M
US$ 1.73
0.06 3.59
443,573
3.00M
US$ 5.190M
US$ 1.15
0.04 3.60
147,735
4.48M
US$ 5.150M
US$ 0.26
0.02 7.04
729,158
19.53M
US$ 5.080M
US$ 3.03
-0.02 -0.66
15,769
1.66M
US$ 5.030M
US$ 9.57
-0.44 -4.40
490,238
505,798
US$ 4.840M
US$ 1.11
-0.15 -11.90
14.33M
4.31M
US$ 4.780M
US$ 1.21
0.00 0.00
103,134
3.93M
US$ 4.760M
US$ 0.39
-0.03 -6.14
4,508
12.26M
US$ 4.740M
US$ 0.23
0.0056 2.54
465,496
20.91M
US$ 4.730M
US$ 2.09
0.11 5.56
6,471
2.25M
US$ 4.700M
US$ 1.98
0.03 1.54
61,468
2.37M
US$ 4.690M
US$ 0.37
0.01 3.04
245,664
12.21M
US$ 4.470M
US$ 1.01
0.02 2.01
562,835
4.43M
US$ 4.470M
US$ 0.74
0.0005 0.07
1,146
5.97M
US$ 4.440M
US$ 0.60
0.00 0.00
0
7.24M
US$ 4.350M
US$ 0.16
0.00 0.00
0
27.76M
US$ 4.300M
C$ 0.04
0.00 0.00
11,000
121.27M
C$ 4.240M
C$ 0.01
0.005 100.00
13,427
418.56M
C$ 4.190M
US$ 2.94
-0.13 -4.23
47,682
1.36M
US$ 4.000M
US$ 0.88
0.005 0.57
81,006
4.48M
US$ 3.960M
US$ 3.57
0.15 4.39
62,212
1.09M
US$ 3.890M
US$ 0.64
-0.0035 -0.54
32,635
6.03M
US$ 3.860M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 1.35
0.21 18.42
292,821
2.78M
US$ 3.750M
US$ 3.10
0.49 18.77
323,292
1.21M
US$ 3.750M
US$ 2.13
0.06 2.90
9,540
1.75M
US$ 3.730M
US$ 1.80
0.03 1.69
42,691
2.05M
US$ 3.690M
C$ 0.10
0.02 18.75
3,500
38.74M
C$ 3.680M
US$ 0.54
-0.07 -10.85
3.31M
6.79M
US$ 3.630M
US$ 1.12
0.03 2.75
5,533
3.22M
US$ 3.610M
US$ 0.50
0.01 2.04
17,472
6.96M
US$ 3.480M
US$ 1.30
0.09 7.44
5,957
2.68M
US$ 3.480M
US$ 2.67
0.04 1.63
6,704
1.27M
US$ 3.390M
US$ 4.68
0.28 6.36
13,332
718,078
US$ 3.360M
US$ 0.07
0.00 0.00
0
47.10M
US$ 3.300M
US$ 2.09
0.02 0.97
69,821
1.49M
US$ 3.110M
US$ 0.41
-0.008 -1.93
162,891
7.63M
US$ 3.110M
US$ 0.96
0.01 1.31
18,839
3.23M
US$ 3.100M
C$ 0.01
0.00 0.00
0
308.61M
C$ 3.090M
US$ 0.31
-0.02 -4.62
154,750
9.94M
US$ 3.080M
C$ 0.04
0.00 0.00
0
76.84M
C$ 3.070M
US$ 1.88
-0.08 -4.08
5,035
1.60M
US$ 3.010M
US$ 4.04
0.14 3.59
3,340
736,431
US$ 2.980M
US$ 3.24
-0.14 -4.14
37,447
914,234
US$ 2.960M
US$ 0.62
-0.01 -1.59
26,412
4.75M
US$ 2.940M
US$ 2.40
0.00 0.00
0
1.21M
US$ 2.900M
US$ 0.32
-0.0002 -0.06
500,319
8.99M
US$ 2.880M
US$ 3.35
-0.05 -1.47
1,962
852,996
US$ 2.860M
C$ 0.02
0.00 0.00
14,000
141.96M
C$ 2.840M
US$ 0.73
-0.0059 -0.80
12,330
3.81M
US$ 2.800M
US$ 0.34
-0.01 -3.43
2.39M
8.29M
US$ 2.780M
US$ 0.34
0.01 4.24
637,778
8.09M
US$ 2.780M
US$ 0.84
-0.01 -1.53
126,451
3.27M
US$ 2.740M
US$ 1.17
0.03 2.63
74,678
2.34M
US$ 2.740M
US$ 0.59
0.03 5.41
6,053
4.52M
US$ 2.670M
US$ 1.16
-0.10 -7.94
1.53M
2.30M
US$ 2.670M
US$ 0.19
0.0009 0.48
6.69M
14.23M
US$ 2.660M
US$ 0.52
-0.03 -4.59
75,543
5.09M
US$ 2.650M
US$ 0.52
-0.05 -8.61
371,382
5.05M
US$ 2.630M
US$ 0.52
-0.01 -2.43
364,665
4.89M
US$ 2.530M
US$ 1.23
0.15 13.89
3.43M
2.04M
US$ 2.510M
US$ 1.75
0.00 0.00
86,637
1.43M
US$ 2.500M
US$ 3.58
-0.18 -4.79
66,708
696,249
US$ 2.490M
US$ 0.23
0.02 9.24
2.23M
10.36M
US$ 2.410M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 2.24
0.48 27.27
11.07M
1.06M
US$ 2.370M
US$ 4.71
0.30 6.80
65,998
500,327
US$ 2.360M
US$ 1.57
0.02 1.29
79,474
1.44M
US$ 2.260M
US$ 0.16
0.00 0.00
0
13.95M
US$ 2.250M
US$ 3.87
-0.12 -3.01
20,676
580,840
US$ 2.250M
US$ 0.34
0.02 6.49
329,602
6.29M
US$ 2.130M
C$ 0.02
0.00 0.00
0
140.03M
C$ 2.100M
US$ 0.003
-0.0001 -3.23
35,925
635.88M
US$ 1.910M
C$ 0.07
0.005 7.69
10,440
27.30M
C$ 1.910M
US$ 0.07
0.00 0.00
0
28.68M
US$ 1.870M
US$ 0.60
0.00 0.00
0
2.83M
US$ 1.700M
US$ 0.03
-0.11 -78.62
151,444
54.39M
US$ 1.690M
US$ 0.53
0.00 0.00
0
2.96M
US$ 1.560M
US$ 0.32
0.00 0.00
0
4.85M
US$ 1.530M
US$ 1.75
-0.22 -10.94
2,694
863,788
US$ 1.510M
US$ 0.92
-0.0001 -0.01
1,333
1.55M
US$ 1.430M
C$ 0.16
-0.01 -5.88
700
8.86M
C$ 1.420M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.30
0.007 2.37
572,665
4.29M
US$ 1.300M
US$ 1.44
-0.12 -7.69
293,180
837,659
US$ 1.210M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.21
-0.09 -30.51
1,075
4.44M
US$ 910K
US$ 0.14
-0.02 -13.75
3.50M
6.58M
US$ 908K
US$ 0.03
0.00 0.00
0
29.49M
US$ 796K
C$ 0.005
0.00 0.00
0
148.32M
C$ 742K
US$ 0.07
-0.62 -90.41
181,477
10.88M
US$ 718K
US$ 0.002
0.0003 17.65
26,797
302.90M
US$ 606K
US$ 0.005
0.00 0.00
0
80.85M
US$ 404K
US$ 0.28
0.07 32.86
4,627
1.39M
US$ 388K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.004
0.00 0.00
0
61.76M
US$ 247K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.01
0.00 0.00
0
12.23M
US$ 147K
US$ 0.03
0.00 0.00
0
3.41M
US$ 109K
US$ 0.001
-0.32 -99.68
116
18.98M
US$ 19K
US$ 0.0001
0.00 0.00
0
30.74M
US$ 3K
US$ 0.00
-0.08 -100.00
1,297
100.08M
US$ -
US$ 3.11
0.00 0.00
28,256
-
US$ -
US$ 3.23
0.00 0.00
991
-
US$ -
US$ 0.00
0.00 0.00
0
44.57M
US$ -
US$ 0.00
-0.04 -100.00
78,328
54.52M
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
51,703
-
US$ -
US$ 0.00
-0.18 -100.00
500
4.70M
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
428,722
-
US$ -
US$ 32.95
0.00 0.00
120,177
-
US$ -
US$ 33.20
0.00 0.00
169,643
-
US$ -
US$ 1.20
0.00 0.00
44,455
-
US$ -
US$ 4.99
0.00 0.00
5,957
-
US$ -
US$ 16.60
0.00 0.00
56,405
-
US$ -
US$ 0.00
-0.17 -100.00
1,000
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
-0.11 -100.00
12,691
112.91M
US$ -

Latest Biotechnology Stock News


PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX100 by the FDA; Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash Runway Beyond Potential NDA... Read more


Vertex Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

BOSTON / Dec 23, 2024 / Business Wire / Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the... Read more


Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 240,000 shares of its common stock at a purchase price of $2.00 per... Read more


Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

AUSTIN, Texas / Dec 23, 2024 / Business Wire / Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), today announced a positive regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil (“THC”),... Read more


Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

LOS ANGELES / Dec 23, 2024 / Business Wire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer were updated to include an addition involving neratinib (NERLYNX®). The updated NCCN Practice Guidelines for Cervical Cancer include neratinib monotherapy for use as second-line or subsequent therapy for recurrent... Read more


NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company... Read more


GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that European Patent Office (EPO) has issued a decision... Read more


Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food... Read more


Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track... Read more


Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave’s first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024... Read more


U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free survival in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) If approved, taletrectinib represents a potential best-in-class treatment option for patients with advanced ROS1+ NSCLC U.S. Food and Drug Administration (FDA) has assigned a target action date... Read more


Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA Fibromyalgia affects more than 10 million adults in the U.S., who are mostly women TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and first new drug for its treatment in more than 15 years NDA... Read more


Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay... Read more


Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. / Dec 23, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE,... Read more


Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical... Read more


Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson’s disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) --... Read more


Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported... Read more


Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). “With regulatory filings for aficamten... Read more


VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors VYN202 demonstrated robust pharmacodynamic activity including evidence of target engagement and significant inhibition of... Read more


Y-mAbs Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA... Read more


RAPT Therapeutics Announces $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock... Read more


Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers   Potent inhibition of drug-resistant and bird flu viruses in vitro In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phase 2 study expected to begin in H1 2025 Traws Pharma is expanding its influenza program to address the potential... Read more


Anavex Life Sciences: Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients with early Alzheimer’s disease Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease patients, demonstrating a favorable safety profile with no associated neuroimaging adverse events NEW YORK, Dec. 23, 2024... Read more


Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life   The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 23 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore”... Read more


RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT obtains worldwide rights excluding China  Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales  Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China  RAPT plans to initiate Phase 2b trial in food allergy next year  RAPT to host a conference call at 8:30 a.m. ET  SOUTH SAN FRANCISCO,... Read more


Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. HENDERSON, Nev. / Dec 23, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the launch of TibuSURE, a Phase 2 global study... Read more


FibroBiologics Announces $25 Million Financing

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by... Read more


Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million. The transaction was structured as a non-convertible, unsecured promissory... Read more


Abivax Announces a Change to the Composition of its Board of Directors

PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director of the... Read more


Devonian Health Reports First Quarter 2025 Financial Results and Grants Stock Options

First quarter revenues increased by 360% year over year First quarter net loss for the quarter of $0.002 per share Grant of 1,535,715 stock options to independent directors QUEBEC CITY / Dec 23, 2024 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its first quarter ended on October 31, 2024. Management Comments “Devonian continued to improve its financial position... Read more


Vertex Pharmaceuticals Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® BOSTON / Dec 20, 2024 / Business Wire / Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved... Read more


Vertex Pharmaceuticals Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time BOSTON / Dec 20, 2024 / Business Wire / Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and... Read more


Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction... Read more


Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.1 PV is a chronic myeloproliferative disorder characterized by aberrant... Read more


Satellos Bioscience Announces Closing of US$40M Public Offering

TORONTO / Dec 20, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced that it has closed an equity offering, issuing a total of 63,285,000 equity securities for gross proceeds of approximately $57 million (USD$40 million) (the “Offering”). “We are thrilled... Read more


BioAtla Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering.... Read more


Renovaro Enters into Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul (www... Read more


Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine 

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. “We are encouraged to see... Read more


TC Biopharm Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

EDINBURGH, Scotland, Dec. 20, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. The ACHIEVE UK clinical... Read more


IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 Commitment is part of the European Investment Bank’s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as immuno-oncology Debt facility expected to extend company’s cash runway into the second quarter of 2026 COPENHAGEN, Denmark and NEW YORK, Dec. 20, 2024 (GLOBE... Read more


Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Neurocrine... Read more


Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance Belapectin was overall well tolerated with no safety signals; incidence of adverse events and serious adverse... Read more


Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit... Read more


InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented:... Read more


Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ®... Read more


Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has... Read more


Verrica Pharmaceuticals Provides Business and Operational Update

Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure Observed significant reduction in YCANTH distributor inventory levels New single applicator configuration for YCANTH® expected to be available in the first quarter of 2025 to help meet growing product demand, reduce acquisition costs for physician practices and expand distribution and patient... Read more


Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Acquisition bolsters Eton’s commercial pediatric endocrinology portfolio Product is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed... Read more


Lexicon Pharmaceuticals Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the FDA aligns with the company’s... Read more


Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB